MicroRNAs May Be Key to Better Immunotherapy for Mesothelioma – Surviving Mesothelioma
Surviving Mesothelioma |
MicroRNAs May Be Key to Better Immunotherapy for Mesothelioma
Surviving Mesothelioma A cell surface protein called PD-L1 is key to the effectiveness of several new immunotherapy drugs including Keytruda (pembrolizumab), Opdivo (nivolumab), and avelumab. An estimated 40 percent of mesothelioma tumors overexpress this protein, which is … |
